{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Investigational
Source:
INN:vadastuximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:balixafortide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00568594: Phase 1/Phase 2 Interventional Completed Coronary Heart Disease
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:paridiprubart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00743002: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rovalpituzumab tesirine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01135108: Phase 2 Interventional Completed Spinal Cord Injury
(2009)
Source URL:
Class:
PROTEIN
KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.
Status:
Investigational
Source:
INN:telisotuzumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT01909245: Phase 2 Interventional Active, not recruiting Type 1 Diabetes Mellitus
(2013)
Source URL:
Class:
PROTEIN
